Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine (Nasdaq: EDIT), a leader in genome editing, announced its participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT), a leader in genome editing, announced its participation in several upcoming investor conferences. The events include the 2022 Wells Fargo Healthcare Conference on September 7, with a 1:55 p.m. ET fireside chat in Everett, MA; the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, at 10:30 a.m. ET in New York, NY; and the Baird 2022 Global Healthcare Conference on September 13 in New York, NY. The chats will be webcast live and archived for 30 days on the company’s website.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was +4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:
- 2022 Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 7, 2022
Time: 1:55 p.m. ET
Location: Everett, MA
- Morgan Stanley 20th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Monday, September 12, 2022
Time: 10:30 a.m. ET
Location: New York, NY
- Baird 2022 Global Healthcare Conference
Date: Tuesday, September 13, 2022
Location: New York, NY
The fireside chats will be webcast live and can be accessed through the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.